SENATE FLOOR VERSION - SB1152 SFLR Page 1
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
SENATE FLOOR VERSION
February 9, 2022
SENATE BILL NO. 1152 By: Standridge
An Act relating to the Uniform Controlled Dangerous
Substances Act; amending 63 O. S. 2021, Section 2-204,
which relates to Schedule I ; modifying inclusions;
and providing an effective date.
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
SECTION 1. AMENDATORY 63 O.S. 2021, Section 2 -204, is
amended to read as follows:
Section 2-204. The controlled substances listed in this s ection
are included in Schedule I and include any material, compound,
mixture or preparation that contains any quan tity of the following
hallucinogenic substance s, their salts, isomers and salts of
isomers, unless specifically excepted, when the existence of these
salts, isomers and salts of isomers is possible within the specific
chemical designation.
A. Any of the following opiates, including their isomers,
esters, ethers, salts, and salts of isomers, esters, a nd ethers,
unless specifically excepted, whe n the existence of these isomers,
esters, ethers, and salts is possible within the specific chemical
designation:
SENATE FLOOR VERSION - SB1152 SFLR Page 2
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1. Acetylmethadol;
2. Allylprodine;
3. Alphacetylmethadol;
4. Alphameprodine;
5. Alphamethadol;
6. Benzethidine;
7. Betacetylmethadol;
8. Betameprodine;
9. Betamethadol;
10. Betaprodine;
11. Clonitazene;
12. Dextromoramide;
13. Dextrorphan (except its methyl ether);
14. Diampromide;
15. Diethylthiambutene;
16. Dimenoxadol;
17. Dimepheptanol;
18. Dimethylthiambutene;
19. Dioxaphetyl butyrate;
20. Dipipanone;
21. Ethylmethylthiambutene;
22. Etonitazene;
23. Etoxeridine;
24. Furethidine;
SENATE FLOOR VERSION - SB1152 SFLR Page 3
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25. Hydroxypethidine;
26. Ketobemidone;
27. Levomoramide;
28. Levophenacylmorphan;
29. Metonitazene;
29. 30. Morpheridine;
30. 31. Noracymethadol;
31. 32. Norlevorphanol;
32. 33. Normethadone;
33. 34. Norpipanone;
34. 35. Phenadoxone;
35. 36. Phenampromide;
36. 37. Phenomorphan;
37. 38. Phenoperidine;
38. 39. Piritramide;
39. 40. Proheptazine;
40. 41. Properidine;
41. 42. Racemoramide; or
42. 43. Trimeperidine.
B. Any of the following opium derivatives, their salts,
isomers, and salts of isomers, unless specifically excepted, when
the existence of these salts, isomers, and salts of isomers is
possible within the specific che mical designation:
1. Acetorphine;
SENATE FLOOR VERSION - SB1152 SFLR Page 4
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
2. Acetyldihydrocodeine;
3. Benzylmorphine;
4. Codeine methylbromide;
5. Codeine-N-Oxide;
6. Cyprenorphine;
7. Desomorphine;
8. Dihydromorphine;
9. Etorphine;
10. Heroin;
11. Hydromorphinol;
12. Methyldesorphine;
13. Methylhydromorphine;
14. Morphine methylbromide;
15. Morphine methylsulfonate;
16. Morphine-N-Oxide;
17. Myrophine;
18. Nicocodeine;
19. Nicomorphine;
20. Normorphine;
21. Phoclodine;
22. Thebacon;
23. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide
(Acetyl fentanyl);
SENATE FLOOR VERSION - SB1152 SFLR Page 5
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
24. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide
(Crotonyl fentanyl);
25. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-
furancarboxamide (Furanyl fentanyl);
26. N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP);
27. N-(1-phenethylpiperidin-4-yl)-N-
phenylcyclopropanecarboxamide (Cyclopropyl fentanyl); or
28. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide
(Butyrl fentanyl).
C. Any material, compound, mixture, or preparation which
contains any quantity of the following hallucinogenic substances,
their salts, isomers, and salts of isomers, unless specifically
excepted, when the existence of these salts, isomers, and salts of
isomers is possible within the specific chemical designation:
1. Methcathinone;
2. 3, 4-methylenedioxy amphetamine;
3. 3, 4-methylenedioxy methamphetamine;
4. 5-methoxy-3, 4-methylenedioxy amphetamine;
5. 3, 4, 5-trimethoxy amphetamine;
6. Bufotenine;
7. Diethyltryptamine;
8. Dimethyltryptamine;
9. 4-methyl-2, 5-dimethoxyamphetamine;
10. Ibogaine;
SENATE FLOOR VERSION - SB1152 SFLR Page 6
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
11. Lysergic acid diethylamide;
12. Marijuana;
13. Mescaline;
14. N-benzylpiperazine;
15. N-ethyl-3-piperidyl benzilate;
16. N-methyl-3-piperidyl benzilate;
17. Psilocybin;
18. Psilocyn;
19. 2, 5 dimethoxyamphetam ine;
20. 4 Bromo-2, 5-dimethoxyamphetamine;
21. 4 methoxyamphetamine;
22. Cyclohexamine;
23. Salvia Divinorum;
24. Salvinorin A;
25. Thiophene Analog of Phencycli dine. Also known as: 1-(1-(2-
thienyl) cyclohexyl) piperidine; 2 -Thienyl Analog of Phenc yclidine;
TPCP, TCP;
26. Phencyclidine (PCP);
27. Pyrrolidine Analog for Phencyclidine . Also known as 1-(1-
Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP;
28. 1-(3-trifluoromethylphenyl) piperazine;
29. Flunitrazepam;
30. B-hydroxy-amphetamine;
31. B-ketoamphetamine;
SENATE FLOOR VERSION - SB1152 SFLR Page 7
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
32. 2,5-dimethoxy-4-nitroamphetamine;
33. 2,5-dimethoxy-4-bromophenethylamine;
34. 2,5-dimethoxy-4-chlorophenethylamine;
35. 2,5-dimethoxy-4-iodoamphetamine;
36. 2,5-dimethoxy-4-iodophenethylamine;
37. 2,5-dimethoxy-4-methylphenethylamine;
38. 2,5-dimethoxy-4-ethylphenethylamine;
39. 2,5-dimethoxy-4-fluorophenethylamine;
40. 2,5-dimethoxy-4-nitrophenethylamine;
41. 2,5-dimethoxy-4-ethylthio-phenethylamine;
42. 2,5-dimethoxy-4-isopropylthio-phenethylamine;
43. 2,5-dimethoxy-4-propylthio-phenethylamine;
44. 2,5-dimethoxy-4-cyclopropylmethylthio -phenethylamine;
45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine;
46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine;
47. 5-methoxy-N, N-dimethyltryptamine;
48. N-methyltryptamine;
49. A-ethyltryptamine;
50. A-methyltryptamine;
51. N, N-diethyltryptamine;
52. N, N-diisopropyltryptamine;
53. N, N-dipropyltryptamine;
54. 5-methoxy-a-methyltryptamine;
55. 4-hydroxy-N, N-diethyltryptamine;
SENATE FLOOR VERSION - SB1152 SFLR Page 8
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
56. 4-hydroxy-N, N-diisopropyltryptamine;
57. 5-methoxy-N, N-diisopropyltryptamine;
58. 4-hydroxy-N-isopropyl-N-methyltryptamine;
59. 3,4-Methylenedioxymethcathinone (Methylone);
60. 3,4-Methylenedioxypyrovalerone (MDPV);
61. 4-Methylmethcathinone (Mephedrone);
62. 4-methoxymethcathinone;
63. 4-Fluoromethcathinone;
64. 3-Fluoromethcathinone;
65. 1-(8-bromobenzo 1,2-b;4,5-b’ difuran-4-yl)-2-aminopropane;
66. 2,5-Dimethoxy-4-chloroamphetamine;
67. 4-Methylethcathinone;
68. Pyrovalerone;
69. N,N-diallyl-5-methoxytryptamine;
70. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone);
71. B-keto-N-Methylbenzodioxolylbutanamine (Butylon e);
72. B-keto-Methylbenzodioxolylpentanamine (Pentylone);
73. Alpha-Pyrrolidinopentiophenone;
74. 4-Fluoroamphetamine;
75. Pentedrone;
76. 4’-Methyl-a-pyrrolidinohexaphenone;
77. 2,5-dimethoxy-4-(n)-propylphenethylamine;
78. 2,5-dimethoxyphenethylamine;
79. 1,4-Dibenzylpiperazine;
SENATE FLOOR VERSION - SB1152 SFLR Page 9
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
80. N,N-Dimethylamphetamine;
81. 4-Fluoromethamphetamine;
82. 4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
(25C-NBOMe);
83. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine
(25I-NBOMe);
84. 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine
(25B-NBOMe);
85. 1-(4-Fluorophenyl)piperazine;
86. Methoxetamine;
87. 3,4-dichloro-N[2-dimethylamino)cyclohexyl] -N-
methylbenzamide;
88. N-ethyl hexadrone;
89. Isopropyl-U-47700;
90. Para-fluorobutyrl fentanyl;
91. Fluoro isobutryrl fentanyl;
92. 3-Hydroxy Phencyclidine (PCP); or
93. 3-methoxy Phencyclidine (PCP) ;
94. Flualprazolam; or
95. Flubromazolam.
D. Unless specifically excepted or unless listed in a di fferent
schedule, any material, compound, mixture, or prepara tion which
contains any quantity of the following substa nces having stimulant
or depressant effect on the central nervous system:
SENATE FLOOR VERSION - SB1152 SFLR Page 10
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
1. Fenethylline;
2. Mecloqualone;
3. N-ethylamphetamine;
4. Methaqualone;
5. Gamma-Hydroxybutyric Acid, also known a s GHB, gamma-
hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, sodium
oxybate, and sodium oxybutyrate;
6. Gamma-Butyrolactone (GBL) as pac kaged, marketed,
manufactured or promoted for human consumption, with the exception
of legitimate food add itive and manufacturing purposes;
7. Gamma Hydroxyvalerate (G HV) as packaged, marketed, or
manufactured for human consumption, with the exception of legitimate
food additive and manufacturing purposes ;
8. Gamma Valerolactone (GVL) as packaged, marketed , or
manufactured for human consumption, with the exception of l egitimate
food additive and manufacturing purposes;
9. 1,4 Butanediol (1,4 BD or BDO) a s packaged, marketed,
manufactured, or promoted for human consumption with the exception
of legitimate manufacturing purposes; or
10. N-ethylpentylone.
E. 1. The following industrial uses of Gamma -Butyrolactone,
Gamma Hydroxyvalerate, Gamma Valerolacton e, or 1,4 Butanediol are
excluded from all schedule s of controlled substan ces under this
title:
SENATE FLOOR VERSION - SB1152 SFLR Page 11
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
a. pesticides,
b. photochemical etching,
c. electrolytes of small batter ies or capacitors,
d. viscosity modifiers in polyurethane,
e. surface etching of metal c oated plastics,
f. organic paint disbursements for water soluble inks,
g. pH regulators in the dyeing of wool and polyamide
fibers,
h. foundry chemistry as a catalyst d uring curing,
i. curing agents in many coating systems based on
urethanes and amides,
j. additives and flavoring agents in food, confection ary,
and beverage products,
k. synthetic fiber and clothing production,
l. tetrahydrofuran production,
m. gamma butyrolactone production,
n. polybutylene terephthalate resin production,
o. polyester raw materials for polyurethane elastomers
and foams,
p. coating resin raw materi al, and
q. as an intermediate in the manufacture of other
chemicals and pharmaceuticals.
2. At the request of any person, the Director may exempt any
other product containing Gamma -Butyrolactone, Gamma Hydroxyvalerate,
SENATE FLOOR VERSION - SB1152 SFLR Page 12
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Gamma Valerolactone, or 1,4 Butanedi ol from being included as a
Schedule I controlled substance if such product is labeled,
marketed, manufactured and distributed for legitimate industrial use
in a manner that reduces or eliminates the likelihood of abuse.
3. In making a determination regar ding an industrial product,
the Director, after notice and hearing, shall consider the
following:
a. the history and current pattern of abuse,
b. the name and labeling of the product ,
c. the intended manner of distribution, advertisi ng and
promotion of the product, and
d. other factors as may be relevant to and consistent
with the public health and safety.
4. The hearing shall be held in accordance with the procedures
of the Administrative Procedures Act.
F. Any material, compound, mixture, or preparation , whether
produced directly or indirectly from a substance of vegetable origin
or independently by means of chemical synthesis, or by a combination
of extraction and chemical synthes is, that contains any quantity of
the following substances, or that contai ns any of their salts,
isomers, and salts of isomers when the existence of these salts,
isomers, and salts of isomers is possible within the specific
chemical designation:
1. JWH-004;
SENATE FLOOR VERSION - SB1152 SFLR Page 13
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
2. JWH-007;
3. JWH-009;
4. JWH-015;
5. JWH-016;
6. JWH-018;
7. JWH-019;
8. JWH-020;
9. JWH-030;
10. JWH-046;
11. JWH-047;
12. JWH-048;
13. JWH-049;
14. JWH-050;
15. JWH-070;
16. JWH-071;
17. JWH-072;
18. JWH-073;
19. JWH-076;
20. JWH-079;
21. JWH-080;
22. JWH-081;
23. JWH-082;
24. JWH-094;
25. JWH-096;
SENATE FLOOR VERSION - SB1152 SFLR Page 14
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
26. JWH-098;
27. JWH-116;
28. JWH-120;
29. JWH-122;
30. JWH-145;
31. JWH-146;
32. JWH-147;
33. JWH-148;
34. JWH-149;
35. JWH-150;
36. JWH-156;
37. JWH-167;
38. JWH-175;
39. JWH-180;
40. JWH-181;
41. JWH-182;
42. JWH-184;
43. JWH-185;
44. JWH-189;
45. JWH-192;
46. JWH-193;
47. JWH-194;
48. JWH-195;
49. JWH-196;
SENATE FLOOR VERSION - SB1152 SFLR Page 15
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
50. JWH-197;
51. JWH-198;
52. JWH-199;
53. JWH-200;
54. JWH-201;
55. JWH-202;
56. JWH-203;
57. JWH-204;
58. JWH-205;
59. JWH-206;
60. JWH-207;
61. JWH-208;
62. JWH-209;
63. JWH-210;
64. JWH-211;
65. JWH-212;
66. JWH-213;
67. JWH-234;
68. JWH-235;
69. JWH-236;
70. JWH-237;
71. JWH-239;
72. JWH-240;
73. JWH-241;
SENATE FLOOR VERSION - SB1152 SFLR Page 16
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
74. JWH-242;
75. JWH-243;
76. JWH-244;
77. JWH-245;
78. JWH-246;
79. JWH-248;
80. JWH-249;
81. JWH-250;
82. JWH-251;
83. JWH-252;
84. JWH-253;
85. JWH-262;
86. JWH-292;
87. JWH-293;
88. JWH-302;
89. JWH-303;
90. JWH-304;
91. JWH-305;
92. JWH-306;
93. JWH-307;
94. JWH-308;
95. JWH-311;
96. JWH-312;
97. JWH-313;
SENATE FLOOR VERSION - SB1152 SFLR Page 17
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
98. JWH-314;
99. JWH-315;
100. JWH-316;
101. JWH-346;
102. JWH-348;
103. JWH-363;
104. JWH-364;
105. JWH-365;
106. JWH-367;
107. JWH-368;
108. JWH-369;
109. JWH-370;
110. JWH-371;
111. JWH-373;
112. JWH-386;
113. JWH-387;
114. JWH-392;
115. JWH-394;
116. JWH-395;
117. JWH-397;
118. JWH-398;
119. JWH-399;
120. JWH-400;
121. JWH-412;
SENATE FLOOR VERSION - SB1152 SFLR Page 18
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
122. JWH-413;
123. JWH-414;
124. JWH-415;
125. CP-55, 940;
126. CP-47, 497;
127. HU-210;
128. HU-211;
129. WIN-55, 212-2;
130. AM-2201;
131. AM-2233;
132. JWH-018 adamantyl-carboxamide;
133. AKB48;
134. JWH-122 N-(4-pentenyl)analog;
135. MAM2201;
136. URB597;
137. URB602;
138. URB754;
139. UR144;
140. XLR11;
141. A-796,260;
142. STS-135;
143. AB-FUBINACA;
144. AB-PINACA;
145. PB-22;
SENATE FLOOR VERSION - SB1152 SFLR Page 19
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
146. AKB48 N-5-Fluorpentyl;
147. AM1248;
148. FUB-PB-22;
149. ADB-FUBINACA;
150. BB-22;
151. 5-Fluoro PB-22; or
152. 5-Fluoro AKB-48.
G. In addition to those substances listed in subsection F of
this section, unless specifically excepted or unless listed in
another schedule, any material, compound, mixture, or preparation
which contains any quantity of a synthetic cannabinoid found to be
in any of the following chemical groups:
1. Naphthoylindoles: any compound containing a 3-(1-
naphthoyl)indole structure with or without substitution at the
nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalk yl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-
2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
halophenyl group, whether or not further substituted on the indole
ring to any extent, an d whether or not substituted on the naphthyl
ring to any extent. Naphthoylindoles include, but are not limited
to:
SENATE FLOOR VERSION - SB1152 SFLR Page 20
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-
200),
b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201),
c. 1-pentyl-3-(1-naphthoyl)indole (JWH-018),
d. 1-butyl-3-(1-naphthoyl)indole (JWH-073),
e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH -081),
f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH -015),
g. 1-hexyl-3-(1-naphthoyl)indole (JWH -019),
h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122),
i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210),
j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH -398),
k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007),
l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH -164),
m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole
(JWH-098),
n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-412),
o. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-
naphthoyl)indole (AM -1220),
p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole
(MAM-2201), or
q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM-2232);
2. Naphthylmethylindoles: any compound c ontaining a 1H-indol-3-
yl-(1-naphthyl)methane structure with or without substitution a t the
nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,
SENATE FLOOR VERSION - SB1152 SFLR Page 21
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
alkenyl, cycloalkylme thyl, cycloalkylethyl, benzyl, halobenzyl, 1 -
(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-
2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
halophenyl group, whether or not further substituted on the indole
ring to any extent, and whether o r not substituted on the naphthyl
ring to any extent. Naphthylmethylindoles include, but are not
limited to, (1-pentylindol-3-yl)(1-naphthyl)methane (JWH -175);
3. Naphthoylpyrroles: any compound containing a 3-(1-
naphthoyl)pyrrole structure with or witho ut substitution at the
nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
phenyl, or halophenyl group, whether or not further substituted on
the pyrrole ring to any extent, and whe ther or not substituted on
the naphthyl group to an y extent. Naphthoylpyrroles include, but
are not limited to:
a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (J WH-147),
b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole
(JWH-370),
c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH-030), or
d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH -147);
SENATE FLOOR VERSION - SB1152 SFLR Page 22
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
4. Naphthylideneindenes: any compound containing a 1 -(1-
naphthylmethylene)indene structure with or without substitution at
the 3-position of the indene ring by an alkyl, haloal kyl,
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloal kylethyl, benzyl,
halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2 -(4-
morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
phenyl, or halophenyl group, whether or not further substituted on
the indene group to any extent, and whether or not substituted on
the naphthyl group to any extent. Naphthylmethylindenes include,
but are not limited to, (1 -[(3-pentyl)-1H-inden-1-
ylidene)methyl]naphthalene (JWH-176);
5. Phenylacetylindoles: any compound conta ining a 3-
phenylacetylindole structure with or without substitution at the
nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethy l, benzyl, halobenzyl, 1-
(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-
2-pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
halophenyl group, whether or not further subst ituted on the indole
ring to any extent, and whethe r or not substituted on the phenyl
ring to any extent. Phenylacetylindoles include, but are not
limited to:
a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH -250),
SENATE FLOOR VERSION - SB1152 SFLR Page 23
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole
(RCS-8),
c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH -203),
d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH -251),
e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH-201), or
f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH -302);
6. Cyclohexylphenols: any compound containing a 2 -(3-
hydroxycyclohexyl)phenol struc ture with or without substitution at
the 5-position of the phenolic ring by an alkyl, haloalky l,
cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl,
halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-
morpholinyl)ethyl, 1 -(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, (tetrahydropyran -4-yl)methyl, 1-methylazepanyl,
phenyl, or halophenyl group, and whether or not further substituted
on the cyclohexyl rin g to any extent. Cyclohexylphenols include,
but are not limited to:
a. 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-
hydroxycyclohexyl]-phenol (CP-47,497),
b. 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-
phenol (cannabicyclohexanol; CP -47,497 C8 homologue) ,
or
c. 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-
hydroxypropyl)cyclohexyl]-phenol (CP 55, 940);
SENATE FLOOR VERSION - SB1152 SFLR Page 24
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
7. Benzoylindoles: any compound conta ining a 3-(benzoyl)indole
structure with or without substitution at the nitrogen atom of the
indole ring by an alk yl, haloalkyl, cyanoalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, ben zyl, halobenzyl, 1-(N-methyl-
2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1-(N-methyl-2-
pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
halophenyl group, whether or not further substituted on the indole
ring to any extent, and whether or not substituted on the phenyl
group to any extent. Benzoylindoles include, but are not limited
to:
a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4),
b. 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-
methoxybenzoyl)indole (Pravadoline or WIN 48, 098),
c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM -694),
d. 1-pentyl-3-(2-iodobenzoyl)indole (AM -679), or
e. 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-
iodobenzoyl)indole (AM-2233);
8. Cyclopropoylindoles: Any compound containing a 3-
(cyclopropoyl)indole structure with substitutio n at the nitrogen
atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl , benzyl, halobenzyl, 1-(N-methyl-
2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-
pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
SENATE FLOOR VERSION - SB1152 SFLR Page 25
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
halophenyl group, whether or not further substi tuted in the indole
ring to any extent and whether or not substituted in t he
cyclopropoyl ring to any extent . Cyclopropoylindoles inclu de, but
are not limited to:
a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole
(UR-144),
b. 1-(5-chloropentyl)-3-(2,2,3,3-
tetramethylcyclopropoyl)indole (5Cl -UR-144), or
c. 1-(5-fluoropentyl)-3-(2,2,3,3-
tetramethylcyclopropoyl)indole (XLR11);
9. Indole Amides: Any compound containin g a 1H-Indole-3-
carboxamide structure with or without substitution at the nitrogen
atom of the indole ring by an alkyl, haloalkyl, cyanoalk yl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-
2-piperidinyl)methyl, 2 -(4-morpholinyl)ethyl, 1-(N-methyl-2-
pyrrolidinyl)methyl, 1 -(N-methyl-3- morpholinyl)methyl,
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
halophenyl group, whethe r or not substituted at the carboxamide
group by an adamantyl, naphthyl, phenyl, benzyl, quino linyl,
cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
further substituted in the indole, adamantyl, naphthy l, phenyl,
SENATE FLOOR VERSION - SB1152 SFLR Page 26
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
pyrrole, quninolinyl, or cycloalkyl rings to any extent . Indole
Amides include, but are not limited to:
a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide
(2NE1),
b. N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3-
carboxamide (STS-135),
c. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
indole-3-carboxamide (ADBICA),
d. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
fluoropentyl)-1H-indole-3-carboxamide (5F-ADBICA),
e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide
(NNE1),
f. 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-
carboxamide (5F-NNE1),
g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006),
or
h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide
(5F-SDB-006);
10. Indole Esters: Any compound containing a 1H -Indole-3-
carboxylate structure with or without substitution at the nitrogen
atom of the indole ring b y an alkyl, haloalkyl, cyanoalkyl, alkenyl,
cycloalkylmethyl, cycloalkylet hyl, benzyl, halobenzyl, 1 -(N-methyl-
2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-2-
pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
SENATE FLOOR VERSION - SB1152 SFLR Page 27
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
halophenyl group, whet her or not substituted at the carboxylate
group by an adamantyl, naphthy l, phenyl, benzyl, quinolinyl,
cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
further substituted in the in dole, adamantyl, naphthyl, phenyl,
pyrrole, quinolinyl, or cycloalkyl rings to any extent . Indole
Esters include, but are not limite d to:
a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-
22),
b. quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate (5F-PB-22),
c. quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-
carboxylate (BB-22),
d. naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-
carboxylate (FDU-PB-22), or
e. naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate (NM2201);
11. Adamantanoylindoles: Any compound containing an
adamantanyl-(1H-indol-3-yl)methanone structure with or without
substitution at the nitrogen atom of the indole ring by an alkyl,
haloalkyl, cyanoalkyl, alkenyl, cycloalkylmet hyl, cycloalkylethyl,
benzyl, halobenzyl, 1 -(N-methyl-2-piperidinyl)methyl, 2 -(4-
SENATE FLOOR VERSION - SB1152 SFLR Page 28
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1 -(N-methyl-3-
morpholinyl)methyl, (tetrahydrop yran-4-yl)methyl, 1-methylazepanyl,
phenyl, or halophenyl group, whether o r not further substituted in
the indole ring to any extent and whether or not substituted in t he
adamantyl ring to any extent . Adamantanoylindoles include, but are
not limited to:
a. adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-
indol-3-yl]methanone (AM1248), or
b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone (AB-
001);
12. Carbazole Ketone: Any compound containing (9H -carbazole-3-
yl) methanone structure with or without s ubstitution at the nitrogen
atom of the carbazole r ing by an alkyl, haloal kyl, cyanoalkyl,
alkenyl, cycloalkylmeth yl, cycloalkylethyl, benzyl, halobenzyl, 1 -
(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-
2-pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or
halophenyl group, with substi tution at the carbon of the methanone
group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl,
cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
further substituted at the carbazole, adamantyl, naphthyl, phenyl,
pyrrole, quinolinyl, or cycloalkyl r ings to any extent. Carbazole
SENATE FLOOR VERSION - SB1152 SFLR Page 29
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Ketones include, but are not limited to, na phthalen-1-yl(9-pentyl-
9H-carbazol-3-yl)methanone (EG-018);
13. Benzimidazole Ketone : Any compound containing
(benzimidazole-2-yl) methanone structure with or without
substitution at either nitrogen atom of the benzimidazole ring b y an
alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,
cycloalkylethyl, benzyl, halobenzyl, 1 -(N-methyl-2-
piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1 -(N-methyl-2-
pyrrolidinyl)methyl, 1 -(N-methyl-3-morpholinyl)methyl,
(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, pheny l, or
halophenyl group, with substituti on at the carbon of the methanone
group by an adamantyl , naphthyl, phenyl, benzyl, quinolinyl,
cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3,3-dimethyl-
1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3,3-
dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not
further substituted in the benzimidazole, adamantyl, naphthyl,
phenyl, pyrrole, quinolinyl, or cycloalkyl ri ngs to any extent.
Benzimidazole Ketones include, but are not limited to:
a. naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-
l)methanone (JWH-018 benzimidazole analog), or
b. (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-
yl)(naphthalen-1-yl)methanone (FUBIMINA ); and
SENATE FLOOR VERSION - SB1152 SFLR Page 30
(Bold face denotes Committee Amendments) 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
14. Modified by Replacement: any compound defined in this
subsection that is modified by replacement of a carbon with nitrogen
in the indole, naphthyl, indene, benzimidazole, or carbazole ring.
H. Any prescription drug approved by the federal Foo d and Drug
Administration under the pr ovisions of Section 505 of the Federal
Food, Drug and Cosmetic Act , Title 21 of the United States Code,
Section 355, that is designated, rescheduled or del eted as a
controlled substance under federal law by the United States Drug
Enforcement Administration shall be exc luded from Schedule I a nd
shall be prescribed, distributed , dispensed or used in accordance
with federal law upon the issuance of a notice, final rule or
interim final rule by the United States Drug Enforc ement
Administration designating, rescheduling or deleting as a controlled
substance such a drug product unde r federal law, unless and until
the Board of Pharmacy takes action pursuant to Section 2 -201 of this
title. If the Board of Pharmacy does not take action pursuant to
Section 2-201 of this title, the drug product shall be deemed to be
designated, reschedul ed or deleted as a controlled substance in
accordance with federal law and in compliance with the Uniform
Controlled Dangerous Substances Act .
SECTION 2. This act shall become effective November 1, 2022.
COMMITTEE REPORT BY: COMMITTEE ON HEALTH AND HUMAN SERVICES
February 9, 2022 - DO PASS